"Belgium Pharmaceuticals & Healthcare Report Q3 2011" now available at Fast Market Research

June 19, 2011 - PRLog -- BMI View: Belgium's pharmaceutical market is small in absolute size, but compares favourably with other Western European markets in terms of per-capita expenditure. High value patented medicines dominate the market and account for around three-quarters of sales by value. Belgium is home to a number of medium-sized pharmaceutical companies such as UCB and Omega Pharma as well as an expanding biotech scene.

Headline Expenditure Projections

* Pharmaceuticals: EUR4.65bn (US$6.17bn) in 2010 to EUR4.69bn (US$6.70bn) in 2011; +0.8% in local currency terms and +8.7% in US dollar terms. Forecast down slightly from Q211 due to analyst modification.
 * Healthcare: EUR35.57bn (US$47.19bn) in 2010 to EUR36.53bn (US$52.24bn) in 2011; +2.7% in local currency terms and +10.7% in US dollar terms. Forecast unchanged from Q211.
 *  Medical devices: EUR7.70bn (US$10.21bn) in 2010 to EUR8.24bn (US$11.78bn) in 2011; +6.9% in local currency terms and +15.3% in US dollar terms. Forecast unchanged from Q211.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/171450_belgium_pharmaceuticals...
------------------------------------------------------------


Business Environment Rating: Belgium received a Business Environment Rating (BER) of 64.5 out of 100 in Q311, fractionally above the average for the Western Europe region and placing it fifth of the 10 markets surveyed by BMI in the Western Europe region. Although growth in medicine sales is low, the country represents a significant market in absolute terms. Furthermore, per-capita spending is high, there is a sizeable pensionable population and regulations are transparent.

Key Trends & Developments

*  It was announced that that Merck & Co was to end its partnership with Belgium's Galapagos in February 2011. The companies had signed agreements in 2008 and 2009 covering metabolic, cardiovascular and inflammatory diseases. Merck put the decision down to a strategic change in its early discovery programmes.
 *  In April 2011, Belgian cancer diagnosis and therapy company Ion Beam Applications (IBA) acquired a 25.2% stake in German radiopharmaceuticals specialist PET Net from its owner Medical Imaging Research Holding. PET Net is the operator of two commercial sites in Erlangen and Regensburg.


BMI Economic View: Like other European economies, Belgium faces fiscal risks, which will limit public expenditure in the coming years. In the healthcare sector, this could manifest itself on the provider side through more limited investment in healthcare infrastructure and on the purchaser side through increasingly scrupulous cost-effectiveness assessments of new drugs.

BMI Political View: Belgium has been without a permanent government since the 2010 federal elections, despite several attempts by parties to form a coalition. Differences between the two major parties on socioeconomic issues serve to create political uncertainty, with the New Flemish Alliance considered more conservative than the left-leaning Socialist Party. However, BMI believes that this situation poses minimal risk to the healthcare industry. Although a geographically separate healthcare system has been mooted, it remains highly unlikely.

Partial Table of Contents:

SWOT Analysis
- Belgium Pharmaceuticals And Healthcare Industry SWOT
- Belgium Political SWOT
- Belgium Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Western Europe Pharmaceutical Business Environment Ratings, Q311
- Rewards
- Risks
Belgium - Market Summary
Regulatory Regime
- Table: Applications* Received and Processed by the AFMPS/FAGG
- Recent Regulatory Developments
- Intellectual Property Environment
- Pricing Regime
- Price Cuts
- Reimbursement Regime
- Generic Medicines Sector
- OTC Medicines Sector
Industry Trends And Developments
- Epidemiology
- Recent Public Health Developments
- Healthcare Sector
- Healthcare Financing
- Healthcare Sector Developments
- Medical Tourism
- Research And Development Sector
- Clinical Trials
- Medical Device Market
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Health Expenditure Indicators 2007-2015
- Table: Government Health Expenditure Indicators 2007-2015
- Table: Private Health Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Belgium - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Sales Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Device Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Imports & Exports Indicators 2007-2015
- Other Healthcare Data Forecasts
- Key Risks To BMI's Forecasts
Competitive Landscape
- Pharmaceutical Industry
- Recent Company Developments
- Pharmaceutical Wholesale
- Pharmaceutical Retail
Company Monitor
- Leading Local Manufacturers
- UCB Pharma
- Solvay
- Janssen Pharmaceutica
- Omega Pharma
- Galapagos
- Leading Multinational Manufacturers
- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1714...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.